News for 'Sun Pharma'

Now, Isn't Shruti Sweet?

Now, Isn't Shruti Sweet?

Rediff.com22 Dec 2025

Shruti Ramachandran's style lives in that sweet spot where simplicity meets a quiet edge.

Healthcare IPOs See A Surge In 2025

Healthcare IPOs See A Surge In 2025

Rediff.com8 Jan 2026

The surge has come alongside a decline in average issue sizes and more muted listing-day returns compared with last year.

Stock markets end lower in volatile trade

Stock markets end lower in volatile trade

Rediff.com24 Dec 2025

From the 30-Sensex firms, InterGlobe Aviation, Sun Pharma, Asian Paints, Reliance Industries, Hindustan Unilever, and Tata Steel were among the biggest laggards. However, Trent, UltraTech Cement, Maruti, and Power Grid were among the gainers.

Sensex jumps 448 points on fresh fund inflows

Sensex jumps 448 points on fresh fund inflows

Rediff.com19 Dec 2025

From the 30-Sensex firms, Bharat Electronics, Power Grid, Tata Motors Passenger Vehicles, Asian Paints, Reliance Industries, and Bajaj Finserv were among the biggest gainers. However, HCL Tech, Kotak Mahindra Bank, ICICI Bank, and Sun Pharma were the laggards.

Sensex down 78 points on weak global trends

Sensex down 78 points on weak global trends

Rediff.com18 Dec 2025

Among Sensex firms, Sun Pharma, Tata Steel, Power Grid, Asian Paints, NTPC and Bharti Airtel were the biggest laggards. Tata Consultancy Services, Tech Mahindra, Infosys, Adani Ports, Axis Bank and HCL Tech were among the gainers.

Weightloss Drugs Hit 1,000 Crore Mark

Weightloss Drugs Hit 1,000 Crore Mark

Rediff.com22 Dec 2025

'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'

'14+ Anti-Obesity Drugs In The Pipeline'

'14+ Anti-Obesity Drugs In The Pipeline'

Rediff.com13 Dec 2025

The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.

Cancer Therapies Break New Ground

Cancer Therapies Break New Ground

Rediff.com26 Dec 2025

'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'

Ozempic launched in India, priced at Rs 2,200 per week

Ozempic launched in India, priced at Rs 2,200 per week

Rediff.com12 Dec 2025

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits.

Sensex jumps nearly 450 pts on buying in metal shares

Sensex jumps nearly 450 pts on buying in metal shares

Rediff.com12 Dec 2025

Among Sensex firms, Tata Steel, Eternal, UltraTech Cement, Larsen & Toubro, Maruti and Bharti Airtel were the major gainers. However, Hindustan Unilever, Sun Pharma, ITC and Asian Paints were among the laggards.

Kapil Sharma-Priyanka Provide The Laughs On OTT

Kapil Sharma-Priyanka Provide The Laughs On OTT

Rediff.com19 Dec 2025

It's raining sequels on OTT this week, but that's not all. Sukanya Verma lists everything you can watch.

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Rediff.com31 Jul 2025

India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.

Can MFN Pricing Reshape India-US Pharma Equation?

Can MFN Pricing Reshape India-US Pharma Equation?

Rediff.com5 Jun 2025

US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).

Will India continue to remain an attractive FDI destination in 2026?

Will India continue to remain an attractive FDI destination in 2026?

Rediff.com27 Dec 2025

FDI inflows into India are expected to register robust growth in 2026, supported by strong macroeconomic fundamentals, big-ticket investment announcements, sustained efforts to improve the ease of doing business, and a new generation of investment-linked trade pacts.

Sensex climbs over 158 points on buying in tech and IT shares

Sensex climbs over 158 points on buying in tech and IT shares

Rediff.com4 Dec 2025

Tata Consultancy Services, Tech Mahindra, Infosys, HCL Tech, Bharti Airtel, Sun Pharma, Bharat Electronics and Trent were the major gainers among Sensex scrips. However, Maruti, Eternal, Kotak Mahindra Bank and Titan were among the laggards.

Cough syrup deaths: Pharma co to face criminal action

Cough syrup deaths: Pharma co to face criminal action

Rediff.com8 Oct 2025

Tamil Nadu Government will take criminal action against a drug manufacturer, whose cough syrup has been banned in the wake of children's deaths in Madhya Pradesh, state minister Ma Subramanian said here on Wednesday.

No deaths due to codeine syrup, accused linked to SP: Yogi

No deaths due to codeine syrup, accused linked to SP: Yogi

Rediff.com22 Dec 2025

Uttar Pradesh Chief Minister Yogi Adityanath on Monday strongly rebutted allegations by Leader of Opposition Mata Prasad Pandey over 'deaths' allegedly due to the consumption of fake medicines and codeine syrup, asserting in the Assembly that no such case has come to the notice of the state government so far.

Stock markets end flat in highly volatile trade

Stock markets end flat in highly volatile trade

Rediff.com28 Nov 2025

Among Sensex firms, Power Grid, Eternal, Bharti Airtel, Axis Bank and Infosys were the biggest laggards. However, Mahindra & Mahindra, Sun Pharma, Kotak Mahindra Bank and State Bank of India were among the major gainers.

Stock markets rally as RBI cuts rate; Sensex jumps 447 points

Stock markets rally as RBI cuts rate; Sensex jumps 447 points

Rediff.com5 Dec 2025

From the Sensex firms, State Bank of India, Bajaj Finserv, Bajaj Finance, Maruti, HCL Tech, Larsen & Toubro, Mahindra & Mahindra and Infosys were among the major winners. However, Hindustan Unilever, Eternal, Tata Motors Passenger Vehicles, and Sun Pharma were among the laggards.

Trump slaps 100% tariffs on imported pharma products

Trump slaps 100% tariffs on imported pharma products

Rediff.com26 Sep 2025

United States President Donald Trump on Friday announced that his administration will impose a 100 per cent tariff on branded and patented pharmaceutical products beginning October 1, 2025, unless the manufacturing companies are building production facilities in the US.

Sensex, Nifty close marginally lower after hitting fresh lifetime highs

Sensex, Nifty close marginally lower after hitting fresh lifetime highs

Rediff.com1 Dec 2025

Among Sensex firms, Bajaj Finance, Sun Pharma, Trent, Mahindra & Mahindra, State Bank of India and Bajaj Finserv were the major laggards. However, Tata Motors Passenger Vehicles, Maruti, Bharat Electronics, Kotak Mahindra Bank, Adani Ports and HCL Tech were among the gainers.

'I Didn't Want To Do Bigg Boss, But...'

'I Didn't Want To Do Bigg Boss, But...'

Rediff.com10 Dec 2025

JioStar's SouthUnbound event served as the launchpad for several new original projects on the streaming platform.

Netra Mantena's Fab Bridal Looks

Netra Mantena's Fab Bridal Looks

Rediff.com25 Nov 2025

From beautifully decorated venues glowing under fairy lights to celebrity guests' dance performances, every function felt straight out of a Bollywood dream sequence. The biggest scene stealer, however, was Netra's wedding wardrobe.

Sensex drops over 331 points on last-minute selling

Sensex drops over 331 points on last-minute selling

Rediff.com24 Nov 2025

Among Sensex firms, Bharat Electronics, Mahindra & Mahindra, Tata Steel, UltraTech Cement, Bajaj Finserv and Tata Motors Passenger Vehicles were the major laggards. However, Tech Mahindra, Asian Paints, Infosys, Adani Ports, Sun Pharma and HDFC Bank were the gainers.

Not neutral, India is on the side of peace, Modi tells Putin

Not neutral, India is on the side of peace, Modi tells Putin

Rediff.com5 Dec 2025

Prime Minister Narendra Modi strongly supported efforts to end the war in Ukraine and conveyed to Russian President Vladimir Putin that India will stand shoulder-to-shoulder in all peace efforts to find an amicable solution to the conflict.

Indian pharma firms not copying products of Swiss cos: Goyal

Indian pharma firms not copying products of Swiss cos: Goyal

Rediff.com10 Jun 2025

Dismissing allegations that Indian phacosrmaceutical companies copy products of Swiss firms, Commerce and Industry Minister Piyush Goyal on Tuesday said it is a long-standing myth and India respects intellectual property rights and never steals technology from others. He said that Swiss pharmaceutical companies have not shown even a single instance that Indian companies have illegally copied any of their trademarks or patents or copyrighted technology.

Sensex jumps over 513 points on buying in IT stocks

Sensex jumps over 513 points on buying in IT stocks

Rediff.com19 Nov 2025

From the Sensex pack, HCL Tech, Infosys, Tata Consultancy Services, Hindustan Unilever, Sun Pharma and Titan were among the biggest gainers. In contrast, Tata Motors Passenger Vehicles, Maruti, Adani Ports and Bajaj Finance were among the laggards.

India terms EU envoys' article unusual before key Putin visit

India terms EU envoys' article unusual before key Putin visit

Rediff.com3 Dec 2025

India and Russia are poised to sign multiple agreements to bolster cooperation in various sectors, including trade and healthcare, during Russian President Vladimir Putin's visit to New Delhi. Discussions will also address the Ukraine conflict and efforts to increase Indian exports to Russia.

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Rediff.com13 Aug 2025

Among Sensex firms, Bharat Electronics, Eternal, Mahindra & Mahindra, Kotak Mahindra Bank, Tata Motors and Power Grid were the gainers. However, Adani Ports, ITC, UltraTech Cement and Titan were among the laggards.

JioHotStar Is Investing 4K Cr In South!

JioHotStar Is Investing 4K Cr In South!

Rediff.com10 Dec 2025

The platform has seen a growth of 70% in watch time for South content, which is more than the national average.The South has outperformed the rest of India in subscription depth, retention and connected TV adoption.

Sensex rises 317 pts on gains in auto, pharma shares

Sensex rises 317 pts on gains in auto, pharma shares

Rediff.com15 Jul 2025

Stock markets snapped the four-day falling streak on Tuesday with the benchmark Sensex rebounding by 317 points on buying in auto and pharma shares amid a decline in retail inflation to a more than six-year low, nearing the RBI's comfort zone. The 30-share BSE Sensex climbed 317.45 points or 0.39 per cent to settle at 82,570.91. During the day, it jumped 490.16 points or 0.59 per cent to 82,743.62. The 50-share NSE Nifty edged higher by 113.50 points or 0.45 per cent to 25,195.80.

Startups go vertical in India's qcom race

Startups go vertical in India's qcom race

Rediff.com24 Oct 2025

As the quick commerce (qcom) race hots up, a new model - vertical qcom - is gaining investor attention. Unlike horizontal players such as Blinkit, Zepto, and Swiggy Instamart, which stock everything from groceries to gifts and gadgets, vertical platforms focus on depth over breadth.

Weak guidance may hit Sun Pharma in FY26

Weak guidance may hit Sun Pharma in FY26

Rediff.com1 Jun 2025

Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with.

Sensex jumps 1,022.50 points; Nifty inches near record high

Sensex jumps 1,022.50 points; Nifty inches near record high

Rediff.com26 Nov 2025

Among Sensex firms, Bajaj Finserv, Bajaj Finance, Tata Steel, Reliance Industries, Sun Pharma, Tata Motors Passenger Vehicles, Axis Bank and Infosys were among the major gainers. Bharti Airtel and Asian Paints emerged as the laggards from the pack.

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Rediff.com30 Jun 2025

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

The Lady Who Designed The Billionaire Wedding

The Lady Who Designed The Billionaire Wedding

Rediff.com9 Dec 2025

When Chennai-based Wedding Designer Ambika Gupta first received a brief for a destination wedding in Udaipur, she had no idea it would turn into one of the most high-profile celebrations of the season.

Putin to land in Delhi soon, Modi to host private dinner

Putin to land in Delhi soon, Modi to host private dinner

Rediff.com4 Dec 2025

Prime Minister Narendra Modi will host Russian President Vladimir Putin for a private dinner and summit, focusing on defence, trade, and geopolitical issues, including the Ukraine conflict and the impact of US sanctions.

Rupee Fall: Who Stands To Gain?

Rupee Fall: Who Stands To Gain?

Rediff.com25 Nov 2025

So far this year, the rupee has fallen by 4.2 per cent, the worst among its Asian peers.

Modi and Putin: Hug in airport, ride in car, dinner at 7, LKM

Modi and Putin: Hug in airport, ride in car, dinner at 7, LKM

Rediff.com5 Dec 2025

Russian President Vladimir Putin arrived in New Delhi for a two-day visit focused on strengthening ties with India, including defense cooperation and trade, amidst a changing geopolitical landscape.

USFDA's new draft biosimilar rules to benefit Indian biotech cos

USFDA's new draft biosimilar rules to benefit Indian biotech cos

Rediff.com9 Nov 2025

The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.